The purpose of this study is to investigate the effects of rosuvastatin treatment on degree of intracranial arterial stenosis.
The purpose of this study is to investigate the effects of rosuvastatin treatment on degree of intracranial arterial stenosis in two years. Dyslipidemia patients with intracranial arterial stenosis will be enrolled under informed consent in this study. Rosuvastatin (5mg) will be orally administered once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8mmol/L. Primary outcome is the progression of intracranial stenosis on magnetic resonance angiography (MRA) after two years.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
60
Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
Tokyo Medical University
Shinjuku-ku, Tokyo, Japan
RECRUITINGProgression of intracranial arterial stenosis after two years
Time frame: 6 months, 1 year and 2 years
Any stroke (ischemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage)
Time frame: 6 months, 1 year and 2 years
Ischemic stroke or transient ischemic attack
Time frame: 6 months, 1 year and 2 years
Intracerebral haemorrhage or subarachnoid haemorrhage
Time frame: 6 months, 1 year and 2 years
Death from any cause
Time frame: 6 months, 1 year and 2 years
Cardiovascular events (ischemic stork, cardiac infarction, and other vascular events
Time frame: 6 months, 1 year and 2 years
The change of percentage in LDL-C from baseline
Time frame: 6 months, 1 year and 2 years
The change in HDL-C level from baseline
Time frame: 6 months, 1 year and 2 years
Intracranial haemorrhage
Time frame: 6 months, 1 year and 2 years
Number of cerebral microbleeds on MRI
Time frame: 6 months, 1 year and 2 years
Carotid intima-media thickness
Time frame: 6 months, 1 year and 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Ankle brachial index
Time frame: 6 months, 1 year and 2 years
Brachial-ankle pulse wave velocity
Time frame: 6 months, 1 year and 2 years
Adverse events and adverse drug reactions
Time frame: up to 2 years